Status:
RECRUITING
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Immunoglobulin A Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) pat...
Detailed Description
This will be a prospective, observational study. Data will be collected using the Folia Health platform. Participation in the study will occur through use of the Folia mobile platform, where study par...
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of IgAN, regardless of symptom or treatment history
- Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
- US-based with a proficient understanding of and ability to read the English language
Exclusion Criteria:
None
Key Trial Info
Start Date :
March 4 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06952426
Start Date
March 4 2025
End Date
June 30 2025
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational site
Boston, Massachusetts, United States, 02108